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ABSTRACT
Objectives: Intrathecal drug delivery (ITDD) devices have been shown to be a clinically effective and cost-effective option for
the management of cancer pain and recommended for use in England. The aim of this study is to assess the impact of the
2015 NHS England Clinical Commissioning Policy on the uptake of ITDD pumps for the management of cancer pain or if there
is an ongoing unmet need for this intervention in England.
Materials and Methods: Hospital Episode Statistics (HES) were obtained for all patients undergoing ITDD for the management
of cancer pain between 2014 and January 2020. In addition, HES were utilized to estimate the number of patients with cancer
potentially eligible for ITDD pump during the same period.
Results: The number of patients with cancer and those potentially suitable to receive an ITDD for the management of cancer
pain have increased year on year since 2014. This increase has not been matched by an uptake in the provision of ITDD. Con-
servative estimates suggest that at least 8000 people with cancer pain would be eligible for ITDD; 458 patients received an
intervention for pain management between April 2018 and March 2019 and only 30 ITDD pumps were implanted in that same
period.
Conclusions: We observed a substantial gap between the need and provision of ITDD for patients with refractory cancer pain
in England despite the recommendation for the use of ITDD for this patient population. In addition, we present suggestions
for improvement of access to and provision of ITDD in England.
Keywords: Cancer pain, Hospital Episode Statistics, intrathecal drug delivery pumps, NHS England Clinical Commissioning Pol-
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INTRODUCTION
Pain is a major symptom affecting patients with cancer. Pain
has been found to be a common symptom in people with cancer,
with 56% of patients suffering moderate-to-severe pain at least
monthly and 41% taking strong opioids either alone or with other
drugs for cancer-related pain (1). Cancer pain may be nociceptive,
neuropathic, or mixed (2). It may arise as a result of the disease,
or its treatment (3).
Cancer incidence and prevalence is rising, with the number of
people living with cancer in the UK estimated to rise to 4 million
by 2030 from 2.1 million in 2015 (4). A 2016 systematic review of
the prevalence of pain in patients with cancer reported pain prev-
alence rates of 39.3% after curative treatment; 55.0% during anti-
cancer treatment; 66.4% in advanced, metastatic, or terminal
disease; and 50.7% in studies that included all cancer stages (5).
Overall, 38.0% of the patients reported moderate to severe pain.
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The National Cancer Survivorship Initiative (NCSI) estimate that
10% of cancer survivors, about 200,000 live with chronic moder-
ate to severe pain (6).
NHS England estimated that 5–15% of cancer patients have
refractory pain and require advanced techniques (6). Intrathecal
drug delivery (ITDD) devices have been shown to be a clinically
effective and cost-effective means of pain relief with fewer side
effects than oral opioids in cancer patients and have potential for
improved survival (2,8).
ITDD consists of a catheter inserted into the intrathecal space and
connected to an implanted pump. The catheter tip is placed
according to the pain site to enable targeted drug delivery. The
pump is usually implanted in the subcutaneous tissues of the ante-
rior abdominal wall to enable easy refill and programming. The
pump is an active battery operated and programmable medical
device, which acts as both reservoir of drug and driver to deliver the
drug. Programmable pumps are the gold standard for ITDD (6).
NHS England commissions ITDD as an advanced stage interven-
tion where other conservative interventions have failed or are con-
traindicated and where the uncontrolled pain is causing a significant
impact on physical and mental health (6). NHS England has rec-
ommended ITDD to be used equally in patients with limited life
expectancy as those patients with near normal life expectancy.
As per National Health Service (NHS) cancer data, 303,135 new
cases of cancer were diagnosed in the year 2016 (9). Employing
conservative estimates published previously, at least 15,156 (5%)
patients are likely to have refractory pain and require advanced
techniques.
The aim of this study is to explore the need and contrast this
with the provision of ITDD pumps in the treatment of cancer pain
throughout the NHS in England from 2014 to January 2020.
MATERIALS AND METHODS
Aggregate data were obtained from the Hospital Episode Statis-
tics (HES) database for the years 2014 to January 2020. HES is a
publicly available data source and aggregate data for this study
were provided by Harvey Walsh Ltd under a data sharing agree-
ment issued by the NHS Digital.
Estimates of patients with cancer and pain potentially eligible
for ITDD were derived from HES using cancer-related International
Statistical Classification of Diseases and Related Health Problems
10th revision (ICD-10) codes (see Supporting Information for
codes used) and refined to identify patients with either cancer
receiving palliative care (code Z515), with metastatic spread
(C77/8/9) and those that died (derived from mortality data) as a
proxy for severe/terminal cancer pain. An alternative estimate of
patients with cancer potentially eligible for ITDD were derived
from HES using a combination of cancer-related ICD-10 codes and
Office of Population Censuses and Surveys (OPCS) codes for inter-
ventional pain procedures (ICD-10 and OPCS codes are presented
in Supporting Information). We did not include ICD-10 cancer
codes in D*s as these tend to be mild and noninvasive/malignant
or C44 as these are nonmalignant skin cancers.
ITDD procedural activities for patients with cancer were investi-
gated using OPCS code A543 (implantation of ITDD device adja-
cent to spinal cord) in combination with relevant cancer-related
ICD-10 codes (see Supporting Information for codes used). Since
2017, a healthcare resource group (HRG) code for the implanta-
tion of ITDD specifically for pain management has been
implemented (i.e., AB13Z; insertion of ITDD device for pain man-
agement). Since ITDD for nonmalignant pain is not routinely
commissioned by NHS England (7), we assumed that procedures
coded under AB13Z represented ITDD for cancer pain. ITDD pro-
cedural activity for patients with cancer using AB13Z code was
investigated to substantiate the data derived from the analysis
based on OPCS codes in combination with ICD-10 codes.
RESULTS
The number of people with cancer in HES (England) has contin-
ued to rise year on year since 2014 (Table 1). A similar rise is
observed in HES for cancer patients receiving palliative care, with
metastatic spread and number of deaths up to 2017/18. A reduc-
tion in the total number of patients receiving palliative care and
number of deaths was observed from 2017/18 to 2018/19,
although this reduction is in part due to a proportion of patients
in 2018/19 and 2019/20 not having a full year worth of data post
ICD10 cancer code.
Using a conservative estimate of 5–15% of cancer patients hav-
ing refractory pain and requiring advanced techniques such as
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Table 1. Estimate of Patients With Cancer Pain in England Potentially Suitable for ITDD.
HES year Total cancer
patients
Total cancer
patients with
palliative care *
Total cancer
patients with
metastases *
Total cancer patients
with death*,†,‡
Mean of total cancer
patients with palliative care,
metastases and death
Estimate of cancer
patients requiring
ITDD (5–15%)§
2014/15 727,607 99,900 196,140 190,971 162,337 8117–24,351
2015/16 736,736 104,725 203,480 193,722 167,309 8365–25,096
2016/17 776,454 110,939 219,620 196,972 175,844 8792–26,377
2017/18 801,649 115,759 225,493 198,214 179,823 8991–26,973
2018/19¶ 820,815 117,136 230,684 197,133 181,651 9083–27,248
2019/20 ¶,** 743,748 75,469 193,170 115,534 128,238 6412–19,236
*Up to one year post-ICD10 cancer code.
†Death taken from mortality data.
‡Total died used as a proxy for severe/terminal/pain.
§Based on NHS England estimate that 5–15% of cancer patients have refractory pain and require advanced techniques (7).
¶Not all patients have a full year post-ICD10 cancer code.
**Up to January 2020.
HES, Hospital Episode Statistics; ITDD, intrathecal drug delivery device.
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ITDD (7), at least 8000 people with cancer pain would be poten-
tially eligible for an ITDD procedure.
A total of 458 patients with cancer diagnosis had a pain relief
procedure code between April 2018 and March 2019 (Fig. 1).
Assessment of ITDD implanted for cancer pain shows a
decrease of 55% in the number of patients receiving ITDD from
the year 2014/15 to 2015/16 (Table 2). The number of ITDD
implanted has not increased as a result of the NHS England
commissioning policy in 2015.
Use of cancer-specific procedure code for ITDD AB13Z shows
that only 30 patients per year have received an ITDD for cancer
pain (Table 3).
DISCUSSION
Our results suggest the existence of a large discrepancy
between the number of patients with cancer pain potentially eli-
gible for ITDD and those that receive an ITDD in England. Even
the most conservative estimate of potentially eligible patients
(i.e., 458 patients with cancer pain that received a pain procedure)
is greatly superior to the actual number of ITDD implanted.
ITDD is recommended in England for patients with cancer pain
where other conservative interventions have failed or are con-
traindicated and where the uncontrolled pain is causing a signifi-
cant impact on physical and mental health either with limited life
3
Figure 1. Patients with cancer pain receiving pain management procedures between April 2018 and March 2019 (per commissioning region in England). [Color
figure can be viewed at wileyonlinelibrary.com]
Table 2. Number of ITDD Implanted in NHS England (Using OPCS Code
A543).
HES year Total patients
receiving an ITDD *
Total patients with
cancer receiving an ITDD †
2014/15 378 109
2015/16 289 49
2016/17 268 70
2017/18 279 54
2018/19 265 64
2019/20 ‡ 196 52
*2014–2019 includes ITDD for management of spasticity; 2014 and
2015 includes ITDD for noncancer pain.
†Patients with an ICD10 C code up to 180 days prior to receiving
an ITDD.
‡Up to January 2020.
HES, Hospital Episode Statistics; ITDD, intrathecal drug delivery device.
Table 3. Patients Receiving ITDD for Cancer Pain in the UK From 2017 to
2019 (Using HRG Code AB13Z).
Region YearH–
2017/18 2018/19
South West 5* 5*
South East 5* 5*
Midlands 10 5*
East 5* 5*
North West 5* 5*
North East and Yorkshire 10 15
England 30 30
H– Represents NHS financial year, that is, April to March.
*Figures between 1 and 7 procedures across regions are masked for
patient confidentiality and numbers are rounded to the nearest 5 or 10
under agreement with NHS digital.
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expectancy or with near normal life expectancy (7). Despite the
recommendation in 2015, there is still a clear gap between the
number of ITDD implants per year and the number of patients
with cancer pain potentially eligible for ITDD. The NHS England
policy has not resulted in an increase in the provision of ITDD for
cancer pain. Possible reasons include 1) high initial cost of ITDD
devices; 2) complexity of the therapy interface between a number
of NHS professionals including oncology, palliative care, anesthe-
sia, neurosurgery, pharmacy, and nursing plus community care
including hospices make delivery complex and possible only in
larger centers; NHS England policy document stipulates that
patient referrals are made to the “Multidisciplinary team lead of
specialized pain center only from networked secondary care pain
services or other tertiary specialties, for example, palliative medi-
cine, cancer center, orthopedic (bony metastases)” (6); 3) however,
candidates for ITDD often present with advanced ill health due to
cancer and other comorbidities limiting their ability to travel to
bigger centers for implantation/pump refills and subsequent care;
and 4) lack of licensed, ITDD compatible, therapeutic alternatives
to opioids where opioid tolerance and resistance has developed
following long term systemic opioid therapy.
In line with the NHS England policy, the use of ITDD as part of
a cancer management strategy for patients with limited life
expectancy as well as those patients with near normal life expec-
tancy also has been recommended by the recent European Soci-
ety for Medical Oncology (ESMO) clinical practice guidelines (10).
The ESMO guidelines recommend ITDD earlier in the treatment
pathway than other neurosurgical interventions such as
cordotomy.
NHS policy on ITDD stresses that the service should be a ter-
tiary referral service providing equity of access over England. Data
specific to ITDD for cancer between 2017 and 2019 shows con-
tinuing inequity of access. Access across England could be
improved by adopting a different model of provision of ITDD via
cancer networks of care where patients are implanted in larger
specialized pain centers allied to cancer centers supported by a
regional network of specialist pain centers delivering ongoing
care nearer to the patient’s domicile, in direct liaison with the
implanting center. Specialist pain centers should aim to deliver an
ITDD refill service at the patient’s local NHS facilities and in the
community. In this, Specialist Pain centers can be supported by
ITDD specialist nurses working across regions to facilitate the refill
and management of ITDD particularly in terminally ill cases where
domiciliary or hospice refill become necessary. Pharmacies can
play a key role both for the quality of mixture compounding and
to facilitate home refills (11). Specialist nurses also should aim to
educate and supervise provision of care. A team of regional ITDD
nurses would act as the link between the implanting specialized
center and the regional specialists pain center, providing continu-
ity of care and easing the burden of ITDD refills on specialist cen-
ters where resources may be overstretched. While NHS England
policy recognizes that “The specialized team will work jointly with
the patient’s primary care team, referring secondary care pain
teams and the clinical teams with responsibility for the primary
condition,” (6) the policy fails to describe precisely how the net-
work of primary, secondary, and tertiary care may interact to
ensure best care and timely management of complications even
where patients reside some distance from a specialized center.
The more recently published framework for provision of pain ser-
vices for adults across the UK with cancer or life-threatening dis-
ease (12) presents a more detailed operational guidance on the
interaction between level 3 specialist pain services and level 4
highly specialist services as well as the interaction between these
services and palliative care. Additionally, video conferencing facili-
ties may further enable multidisciplinary meetings with caregivers
in local hospitals to provide additional support. Despite sugges-
tions to improve provision and access to ITDD, dissemination of
information on the technology in particular to cancer patients’
caregivers is paramount to awareness of ITDD for this patient
population, potentially enabling access at an earlier stage of
disease.
The cost implications of cancer pain treatments is an important
consideration because cancer survivors are living longer and may
require many years of analgesia—this is particularly true of adult
survivors of childhood cancers. Cost analyses of ITDD systems per-
formed from a US commercial payer perspective have demon-
strated that ITDD patients afforded lower total healthcare
utilization (and resultant cost savings) compared with conven-
tional opioid therapy alone as early as two months and through
to 12 months postimplant (13). In selected patients on high-cost
conventional opioid regimens, ITDD management of cancer-
related pain can result in cost savings as early as 7.6 months com-
pared with conventional opioid therapy (8). It also has been
reported that public funding from a Canadian regional perspec-
tive for ITDD systems for cancer pain could result in a small bud-
get impact of several hundred thousand (Canadian dollars) per
year, with a potential for cost savings over time (14).
The advantages of using ITDD for cancer pain should be care-
fully weighed with potential disadvantages on an individual
patient basis. Studies have suggested that opioids may have a
role in the development of some tumors (15–17). Nevertheless,
these studies conclude that the clinical relevance and direct effect
of opioids on tumor has not been demonstrated in humans and
animal models have a short duration and findings are not always
translatable to human disease.
In France, the number of ITDD implanted has risen by 20%
annually since 2015 (18). The provision of ITDD is considerably
higher than in England with 245 and 313 devices implanted in
2017 and 2018, respectively (18). These figures exclude ITDD for
spasticity but contain those implanted for noncancer pain. Expert
opinion suggests that currently approximately 300 ± 30 implants
of ITDD are performed in France for a cancer pain indication on
an annual basis (19). The incidence of the use of ITDD for cancer
pain in other countries has not been reported on an annual basis.
A health technology assessment conducted in Belgium reported
that 718 ITDDs were implanted between 2002 and 2008 (20). The
proportion of ITDD that were implanted for cancer pain during
this period is unclear. The authors suggest that the ICD diagnosis
codes for patients receiving an implant were in general rather
unspecific (20). A retrospective study using MarketScan commer-
cial claims data identified 1251 patients receiving ITDD for cancer
pain between January 2009 and September 2015 (13).
Strengths and Weaknesses
To our knowledge, this is the first article to explore the current
provision of ITDD for cancer pain in NHS England and contrast
this with an estimate of the population need for this therapy. Use
of NHS coding data to identify the exact number of ITDD implants
for cancer pain is limited as a specific HRG code (AB13Z) for this
procedure was not introduced until 2017. Thus, estimates for ITDD
provision for cancer pain from 2017 onwards are predicted to be
more accurate. However, even after the introduction of a proce-
dure and condition-specific HRG code, some miscoding may have
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occurred as activity was observed in centers not implanting ITDDs
for cancer. Therefore, despite the low number of ITDD implants for
cancer pain across England reported in our analysis, this may repre-
sent an overestimate of the exact number of ITDD pumps implanted
over the study period. Moreover, the increasing trend observed in
HES for cancer patients receiving palliative care is merely an esti-
mate because hospice data have not been considered.
Despite proven efficacy and the presence of an NHS England
policy recommending its use, to our knowledge few centers pro-
vide ITDD for cancer pain.
In conclusion, we observed a substantial gap between the need
and provision of ITDD for patients with refractory cancer pain in
England. The publication of NHS England commissioning policy
recommending ITDD for this patient population has not resulted
in a decrease of this gap. Provision of ITDD across England can be
improved to address the unmet need for ITDD in cancer pain
patients.
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